For immediate release: May 18, 2004
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will present at the UBS Global Specialty Pharmaceuticals Conference at The Grand Hyatt Hotel in New York, New York on Tuesday, May 25, 2004 at 10:00 am EST.
David Main, INEX’s President and CEO, will give a presentation providing an update on the Company. The presentation will be webcast and can be accessed through the INEX website at www.inexpharm.com for up to 90 days after the presentation.
About INEX
INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer.
The Company’s lead product, Onco TCS, is a targeted chemotherapeutic combining the Company’s proprietary drug delivery technology with the off-patent anticancer drug vincristine. The Company announced in June 2003 that it had achieved positive results in a pivotal phase II/III clinical trial evaluating Onco TCS as a treatment for relapsed aggressive non-Hodgkin’s lymphoma. Onco TCS is also being evaluated in other phase II human clinical trials for lymphoma and other cancers.
INEX announced on March 15, 2004 that it had completed the New Drug Application (NDA) for Onco TCS seeking marketing approval from the United States Food and Drug Administration (FDA).
The Company announced in January 2004 that it had entered into a strategic partnership with Enzon Pharmaceuticals Inc. to develop and commercialize Onco TCS in North America.
There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words “believes,” “may,” “plans,” “will,” “estimate,” “continue,” “anticipates,” “intends,” “expects,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, INEX’s stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market INEX’s products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
INEX investor contact:
Ian Mortimer
Senior Director, Investor Relations
Inex Pharmaceuticals Corporation
Tel: 604.419.3200
Email: info@inexpharm.com
Website: www.inexpharm.com
INEX media contact:
Miriam Zitner
James Hoggan & Associates Inc.
Tel: 604.739.7500
Email: mzitner@hoggan.com
